MX2008012950A - Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos. - Google Patents

Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos.

Info

Publication number
MX2008012950A
MX2008012950A MX2008012950A MX2008012950A MX2008012950A MX 2008012950 A MX2008012950 A MX 2008012950A MX 2008012950 A MX2008012950 A MX 2008012950A MX 2008012950 A MX2008012950 A MX 2008012950A MX 2008012950 A MX2008012950 A MX 2008012950A
Authority
MX
Mexico
Prior art keywords
receptor
growth factor
antibodies against
amount
against insulin
Prior art date
Application number
MX2008012950A
Other languages
English (en)
Spanish (es)
Inventor
Ralf Schumacher
Silke Hansen
Dietmar Reusch
Klaus Peter Kuenkele
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36940705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008012950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2008012950A publication Critical patent/MX2008012950A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2008012950A 2006-04-11 2007-04-10 Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos. MX2008012950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007571 2006-04-11
PCT/EP2007/003165 WO2007115814A2 (en) 2006-04-11 2007-04-10 Antibodies against insulin-like growth factor i receptor and uses thereof

Publications (1)

Publication Number Publication Date
MX2008012950A true MX2008012950A (es) 2008-10-15

Family

ID=36940705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012950A MX2008012950A (es) 2006-04-11 2007-04-10 Anticuerpos contra el receptor del factor i de crecimiento de tipo insulina y sus usos.

Country Status (20)

Country Link
US (1) US20080014203A1 (https=)
EP (2) EP2007810B1 (https=)
JP (1) JP4718634B2 (https=)
KR (2) KR101276513B1 (https=)
CN (1) CN101421305B (https=)
AR (1) AR060592A1 (https=)
AU (1) AU2007236199B2 (https=)
BR (1) BRPI0710185B8 (https=)
CA (2) CA2647181C (https=)
CR (1) CR10301A (https=)
EC (1) ECSP088816A (https=)
ES (1) ES2403075T3 (https=)
IL (1) IL194397A (https=)
MX (1) MX2008012950A (https=)
NO (1) NO20084082L (https=)
NZ (1) NZ571414A (https=)
RU (1) RU2541765C2 (https=)
UA (1) UA95284C2 (https=)
WO (1) WO2007115814A2 (https=)
ZA (1) ZA200808597B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
WO2010112194A1 (en) * 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
BRPI1010068A2 (pt) 2009-07-24 2016-03-15 Hoffmann La Roche "sistema agitador, dispositivo, método para cultivo de células animais, método para produzir um polipeptídeo, uso de um sistema agitador e dispositivos para cultivar células animais"
WO2011044336A2 (en) * 2009-10-07 2011-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (igf) system
WO2011051231A1 (en) 2009-10-26 2011-05-05 F. Hoffmann-La Roche Ag Method for the production of a glycosylated immunoglobulin
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011135040A1 (en) 2010-04-30 2011-11-03 F. Hoffmann-La Roche Ag Fluorescent antibody fusion protein, its production and use
RU2591523C2 (ru) 2010-11-05 2016-07-20 Ф. Хоффманн-Ля Рош Аг Оптимизированный метод захвата антител хроматографией смешанного типа
EA201400046A1 (ru) 2011-06-22 2014-07-30 Ф. Хоффманн-Ля Рош Аг Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
RU2502798C2 (ru) * 2012-02-22 2013-12-27 Общество с ограниченной ответственностью "Фармако Биотех" КЛЕТОЧНАЯ ЛИНИЯ huFSHIK, СЕКРЕТИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ЧЕЛОВЕЧЕСКИЙ ФСГ
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
CA2889788A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
WO2021119234A1 (en) * 2019-12-10 2021-06-17 Horizon Pharma Ireland Ltd. Glycosylated antibodies against insulin-like growth factor i receptor and uses thereof
CN119792512A (zh) 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5610297A (en) * 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7217796B2 (en) * 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
EP1613658B1 (en) * 2003-04-02 2012-03-14 F. Hoffmann-La Roche AG Antibodies against insulin-like growth factor i receptor and uses thereof
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
EP1666501A4 (en) * 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd Sugar chain-modified anti-HM1.24 antibody
EP1693069B1 (en) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor

Also Published As

Publication number Publication date
EP2007810A2 (en) 2008-12-31
BRPI0710185B8 (pt) 2021-05-25
JP4718634B2 (ja) 2011-07-06
ES2403075T3 (es) 2013-05-13
JP2009533367A (ja) 2009-09-17
NO20084082L (no) 2008-11-06
WO2007115814A2 (en) 2007-10-18
RU2541765C2 (ru) 2015-02-20
UA95284C2 (ru) 2011-07-25
EP2363417A1 (en) 2011-09-07
CR10301A (es) 2008-10-29
AU2007236199A1 (en) 2007-10-18
ECSP088816A (es) 2008-11-27
NZ571414A (en) 2011-12-22
BRPI0710185A8 (pt) 2019-01-22
KR20120028396A (ko) 2012-03-22
CA2647181C (en) 2020-08-11
KR20080113233A (ko) 2008-12-29
EP2007810B1 (en) 2013-02-13
AU2007236199B2 (en) 2013-07-25
WO2007115814A3 (en) 2008-01-10
ZA200808597B (en) 2009-11-25
BRPI0710185B1 (pt) 2020-01-14
IL194397A0 (en) 2011-08-01
BRPI0710185A2 (pt) 2011-08-09
US20080014203A1 (en) 2008-01-17
CA3081707A1 (en) 2007-10-18
AR060592A1 (es) 2008-07-02
CN101421305A (zh) 2009-04-29
CN101421305B (zh) 2013-05-15
IL194397A (en) 2014-04-30
KR101276513B1 (ko) 2013-06-21
CA2647181A1 (en) 2007-10-18
RU2008144290A (ru) 2010-05-20

Similar Documents

Publication Publication Date Title
UA95284C2 (ru) Антитела к рецептору инсулинподобного фактора роста i и их применение
TW200833712A (en) Antibodies against insulin-like growth factor I receptor and uses thereof
CA2647288C (en) A cho-dg44 derivative cell line expressing an antibody against insulin-like growth factor receptor 1
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2008006554A3 (en) Glyco-engineered antibodies
UA93488C2 (uk) Композиція анти-гліпікан 3-антитіл, що мають модифікований цукровий ланцюг
EP2365006A3 (en) Novel anti-IGF-IR antibodies and uses thereof
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TN2009000245A1 (en) Human antibodies to human delta like ligand 4
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006115800A3 (en) Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
IL204157A (en) Isolated antibodies or antigen-binding fragments that bind to human protein 5b6 on the surface of dendritic cells, preparations containing them and their use
WO2008079849A3 (en) Antibodies to insulin-like growth factor receptor
NZ616992A (en) Anti-ilt7 antibody
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008094942A3 (en) Humanized antibodies against cxcr3
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2007127160A3 (en) Agrm2 antigen
WO2008036337A8 (en) Predicted phosphorylation sites
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
EP1688437A4 (en) ANTIBODY COMPOSITION SPECIFICALLY BINDING TO IL-5 RECEPTOR

Legal Events

Date Code Title Description
FG Grant or registration